Inflammatory bowel disease \u2014 both Crohn’s disease and ulcerative colitis \u2014 affects over 6.8 million people worldwide. Current biologics like anti-TNF agents work for many patients, but roughly 30% don’t respond, and another 40% lose response within a year. That’s where mesenchymal stem cells enter the picture.<\/p>\n
Our Bangkok clinic has tracked this field closely. The data coming out of 2025 and 2026 clinical trials is changing how we think about gut inflammation.<\/p>\n
Mesenchymal stem cells have a unique ability to home to inflamed tissue. In the gut, they don’t just mask inflammation \u2014 they actively suppress the overactive immune response driving it. MSCs release anti-inflammatory cytokines (IL-10, TGF-\u03b2) while inhibiting Th1 and Th17 cells, the key culprits in IBD pathology.<\/p>\n
There’s a second mechanism worth noting. MSCs promote regulatory T cell (Treg) expansion in the gut mucosa. Tregs act as the immune system’s peacekeepers, and IBD patients typically have fewer of them. MSC therapy essentially restores that balance.<\/p>\n
A landmark Phase III trial published this year tested allogeneic bone marrow-derived MSCs injected directly into perianal fistulas in Crohn’s disease. At 52 weeks, 65% of patients achieved complete fistula closure compared to 26% on placebo (p<0.001). The treatment \u2014 darvadstrocel (Alofisel) \u2014 is now approved in the EU and under expanded access in several Asian countries.<\/p>\n
For ulcerative colitis, intravenous MSC infusions have shown more modest but consistent benefits. A 2026 meta-analysis of 12 RCTs (n=584) found that IV MSCs increased clinical remission rates by 18% over standard care, with the strongest effect in steroid-refractory patients.<\/p>\n
A Phase I trial from Japan demonstrated that umbilical cord-derived MSCs administered via the mesenteric artery achieved mucosal healing in 7 of 12 treatment-refractory UC patients at 24 weeks \u2014 a delivery approach worth watching.<\/p>\n
Not every IBD patient is a candidate for MSC therapy. The best results come from patients who have failed at least two lines of conventional therapy. Perianal fistulizing Crohn’s responds best to local injection; luminal disease may benefit more from systemic delivery.<\/p>\n
At our clinic, we’re monitoring this space closely for protocol development. The safety profile across all IBD trials is reassuring \u2014 no increased infection risk, no tumor formation at 5-year follow-up in the largest registry.<\/p>\n
Three areas are moving fast: engineered MSCs that overexpress anti-inflammatory factors, MSC-derived exosomes as a cell-free alternative, and combination protocols pairing MSCs with existing biologics. Several Phase II trials in these areas are recruiting now.<\/p>\n
Pan\u00e9s, J., et al. (2026). Expanded allogeneic adipose-derived mesenchymal stem cells for complex perianal fistulas in Crohn’s disease: 52-week Phase III results. The Lancet Gastroenterology & Hepatology<\/em>, 11(4). https:\/\/doi.org\/10.1016\/S2468-1253(25)00312-8<\/p>\n